Studies have uncovered that abnormalities in the alpha-synuclein protein are likely a causal factor for numerous diseases, including Parkinson’s disease, multiple system atrophy (MSA), dementia with ...

The results of studies in live mice and in mouse and human brain tissue suggest that one of the normal functions of alpha-synuclein, a protein found in the characteristic Lewy bodies that form in the ...

Amsterdam, NL, November 13, 2019 - Aggregates of the protein alpha-synuclein arising in the gut may play a key role in the development of Parkinson's disease (PD). Investigators are testing the ...

A neurodegenerative disorder characterized by the aggregation of alpha synuclein into Lewy bodies in the brain is known as Parkinson’s Disease (PD). Alpha synuclein is a 14-kDa protein encoded by the ...

In Parkinson's disease and dementia with Lewy bodies, pathological aggregates of misfolded alpha-synuclein protein develop in brain neurons. Researchers have now described changes in hippocampal ...

Serum α-synuclein was found to be increased in children with obesity and type 1 diabetes (T1D), which was linked to the impairment of executive function in these children. A study published in the ...

The sunbird Syn (TM) assay accurately classified Parkinson's disease-positive blood samples with 81% accuracy through the direct detection of EV-bound aggregated alpha-synuclein proteins -- -- With no ...

Changes in shape and structure can turn a well-behaved cellular protein into something altogether more sinister, but in many cases researchers do not know exactly which modifications are at fault. At ...

Novartis is returning to the alpha-synuclein protein as a possible treatment for Parkinson’s disease, signing a licensing deal worth up to $2.2bn for Arrowhead Pharmaceuticals’ preclinical candidate.

A neuron model of Parkinson's disease and Lewy body dementias shows defects that could suggest treatments to halt or reverse cognitive impairments before the neurons die BIRMINGHAM, Ala. - A decay of ...